
Sign up to save your podcasts
Or


Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed now and look toward possible forthcoming treatments. This podcast is part 2 of 2.
By Retina Today4.4
1717 ratings
Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed now and look toward possible forthcoming treatments. This podcast is part 2 of 2.

43 Listeners

2,438 Listeners

5 Listeners

7,213 Listeners

11 Listeners

21 Listeners

51 Listeners

11 Listeners

18 Listeners

0 Listeners

2 Listeners

19 Listeners

0 Listeners

1,533 Listeners

0 Listeners